Role of vascular normalization in benefit from metronomic chemotherapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 8, 2017, Pages 1994-1999

  Mpekris, Fotios ^a   Baish, James W ^b   Stylianopoulos, Triantafyllos ^a   Jain, Rakesh K ^c  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b BUCKNELL UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Drug delivery; Immune response; Oxygenation; Thrompospondin 1; Tumor perfusion

Indexed keywords

CYCLOPHOSPHAMIDE; GEMCITABINE; THROMBOSPONDIN 1; ANTINEOPLASTIC AGENT; THROMBOSPONDIN-1, HUMAN;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEEDBACK SYSTEM; HUMAN; IMMUNOCOMPETENT CELL; LOW DRUG DOSE; MATHEMATICAL MODEL; METRONOMIC DRUG ADMINISTRATION; NATURAL KILLER CELL; PANCREAS TUMOR; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; VASCULAR TUMOR; ANIMAL; CANCER STEM CELL; CELL HYPOXIA; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; THEORETICAL MODEL; VALIDATION STUDY;

ADMINISTRATION, METRONOMIC; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL HYPOXIA; HUMANS; MODELS, THEORETICAL; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSPONDIN 1; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85013173942     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1700340114     Document Type: Article

References (61)

1. Pasquier E, Kavallaris M, André N (2010) Metronomic chemotherapy: New rationale for new directions. Nat Rev Clin Oncol 7(8):455-465.
2. André N, Carré M, Pasquier E (2014) Metronomics: Towards personalized chemotherapy? Nat Rev Clin Oncol 11(7):413-431.
3. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423-436.
4. Browder T, et al. (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878-1886.
5. Klement G, et al. (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105(8):R15-R24.
6. Jain RK (2014) Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26(5):605-622.
7. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK (2002) Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416(6878):279-280.
8. Bertolini F, et al. (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63(15):4342-4346.
9. Shaked Y, et al. (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313(5794):1785-1787.
10. Mancuso P, et al. (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108(2):452-459.
11. Pasquier E, et al. (2013) Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells. Angiogenesis 16(2):373-386.
12. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in anti-angiogenic therapy. Science 307(5706):58-62.
13. Doloff JC, et al. (2009) Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine. Curr Cancer Drug Targets 9(6):777-788.
14. Cham KK, et al. (2010) Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer 103(1):52-60.
15. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7(9):987-989.
16. Huang Y, et al. (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 109(43):17561-17566.
17. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK (2013) Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73(10):2943-2948.
18. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56(5):641-648.
19. Kaneno R, et al. (2011) Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol (Dordr) 34(2):97-106.
20. Kan S, et al. (2012) Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res 32(12):5363-5369.
21. Folkins C, et al. (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67(8):3560-3564.
22. Vives M, et al. (2013) Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. Int J Cancer 133(10):2464-2472.
23. Kerbel RS (2012) Strategies for improving the clinical benefit of antiangiogenic drug-based therapies for breast cancer. J Mammary Gland Biol Neoplasia 17(3-4):229-239.
24. Kerbel RS, Grothey A (2015) Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials. Nat Rev Clin Oncol 12(6):313-314.
25. Jedeszko C, et al. (2015) Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Sci Transl Med 7(282):282ra50.
26. Faivre C, Barbolosi D, Pasquier E, André N (2013) A mathematical model for the administration of temozolomide: Comparative analysis of conventional and metronomic chemotherapy regimens. Cancer Chemother Pharmacol 71(4):1013-1019.
27. Benzekry S, Hahnfeldt P (2013) Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers. J Theor Biol 335:235-244.
28. Panetta JC, Schaiquevich P, Santana VM, Stewart CF (2008) Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res 14(1):318-325.
29. Liao D, Estévez-Salmerón L, Tlsty TD (2012) Generalized principles of stochasticity can be used to control dynamic heterogeneity. Phys Biol 9(6):065006.
30. Hahnfeldt P, Hlatky L, Klement GL (2013) Center of Cancer Systems Biology second annual workshop-tumor metronomics: Timing and dose level dynamics. Cancer Res 73(10):2949-2954.
31. McGuire MF, et al. (2013) Formalizing an integrative, multidisciplinary cancer therapy discovery workflow. Cancer Res 73(20):6111-6117.
32. Schättler H, Ledzewicz U, Amini B (2016) Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy. JMathBiol72(5):1255-1280.
33. Goldman A, et al. (2015) Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nat Commun 6:6139.
34. Conley SJ, et al. (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109(8):2784-2789.
35. Jain RK (2008) Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 8(4):309-316.
36. Mupparaju S, et al. (2011) Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas. Oncol Rep 26(1):281-286.
37. Stylianopoulos T, Jain RK (2013) Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci USA 110(46):18632-18637.
38. Stephens TC, Peacock JH (1977) Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Br J Cancer 36(3):313-321.
39. Davis AJ, Tannock JF (2000) Repopulation of tumour cells between cycles of chemotherapy: A neglected factor. Lancet Oncol 1:86-93.
40. Yapp DT, et al. (2016) The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: Treatment effects on metabolism, vascular function, cell proliferation, and tumor growth. Angiogenesis 19(2):229-244.
41. Pfirschke C, et al. (2016) Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44(2):343-354.
42. Sorensen AG, et al. (2009) A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69(13):5296-5300.
43. Batchelor TT, et al. (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110(47):19059-64.
44. Jain RK (2013) Normalizing tumor microenvironment to treat cancer: Bench to bed-side to biomarkers. J Clin Oncol 31(17):2205-2218.
45. Kerbel RS, Shaked Y (2016) Therapy-activated stromal cells can dictate tumor fate. J Exp Med 213(13):2831-2833.
46. Pries AR, Höpfner M, le Noble F, Dewhirst MW, Secomb TW (2010) The shunt problem: Control of functional shunting in normal and tumour vasculature. Nat Rev Cancer 10(8):587-593.
47. Pries AR, Reglin B, Secomb TW (2001) Structural adaptation of microvascular networks: Functional roles of adaptive responses. Am J Physiol Heart Circ Physiol 281(3):H1015-H1025.
48. Hobbs SK, et al. (1998) Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 95(8):4607-4612.
49. Netti PA, Roberge S, Boucher Y, Baxter LT, Jain RK (1996) Effect of transvascular fluid exchange on pressure-flow relationship in tumors: A proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 52(1):27-46.
50. Baish JW, Netti PA, Jain RK (1997) Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc Res 53(2):128-141.
51. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications. Cancer Res 59(15):3776-3782.
52. Padera TP, et al. (2004) Pathology: Cancer cells compress intratumour vessels. Nature 427(6976):695.
53. de Pillis LG, Radunskaya AE, Wiseman CL (2005) A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res 65(17):7950-7958.
54. Stylianopoulos T, Economides EA, Baish JW, Fukumura D, Jain RK (2015) Towards optimal design of cancer nanomedicines: Multi-stage nanoparticles for the treatment of solid tumors. Ann Biomed Eng 43(9):2291-2300.
55. Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60(12):1421-1434.
56. McGuire BJ, Secomb TW (2001) A theoretical model for oxygen transport in skeletal muscle under conditions of high oxygen demand. J Appl Physiol (1985) 91(5):2255-2265.
57. Eikenberry S (2009) A tumor cord model for doxorubicin delivery and dose optimization in solid tumors. Theor Biol Med Model 6:16.
58. + cancer stem cells in glioblastoma. Mol Cancer 5:67.
59. Bocci G, Francia G, Man S, Lawler J, Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100(22):12917-12922.
60. Hamano Y, et al. (2004) Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64(5):1570-1574.
61. Barsoum IB, Smallwood CA, Siemens DR, Graham CH (2014) A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 74(3):665-674.